Abstract:Background: The TP53 tumor suppressor gene plays an important role in preventing and inhibiting the growth of tumor by regulating cell cycle, apoptosis and DNA repair. Meanwhile, the TP53 gene is one of the most frequently altered gene in non-small cell lung cancer (NSCLC) patients. Mutant TP53 (TP53-MUT) may lose tumor suppressor activity and gain tumor promoting functions, which play an important role in cancer risk, therapy resistance and poor prognosis. The impact of TP53-MUT on the prognosis of NSCLC patients need to be further studied.Methods: We obtained genomic and clinical data from The Cancer Genome Atlas (TCGA). Mutation profiles, the TMB, disease-free survival (DFS), and overall survival (OS) were compared between patients with different TP53-MUT statuses.Results: TP53-MUTs were detected in 46.6% of patients with lung adenocarcinoma (LUAD) (264 of 566) and 82.3% of those with lung squamous cell carcinoma (LUSC) (401 of 487). The most frequently co-mutated genes in patients with LUAD carrying a TP53-MUT included classic driver genes such as epidermal growth factor receptor (EGFR) and anaplastic large-cell lymphoma kinase (ALK), while Kirsten rat sarcoma viral oncogene (KRAS) mutations and TP53-MUTs appear to be mutually exclusive. This mutual exclusivity was not observed in patients with LUSC, in whom titin (TTN) and CUB and Sushi multiple domains 3 (CSMD3) were the most frequently co-mutated genes. A higher TMB was significantly associated with TP53-MUTs in patients with LUAD but not in those with LUSC. In patients with stage I-III NSCLC who had undergone surgery, there was no significant difference in DFS between patients carrying TP53-wildtype (TP53-WT) and TP53-MUTs, irrespective of histology or mutation type. However, the presence of TP53-MUT was associated with shorter OS in patients with LUAD (49 vs. 54 months, respectively; P=0.13) and significantly longer OS in those with LUSC (62 vs. 29 months, respectively; P=0.015).Conclusions: In contrast to most previous studies, we revealed TP53-MUT characteristic in NSCLC patients according to histology-specific differences and the association between TP53-MUT and the mutation landscape, the TMB, and the OS. These findings suggest a need for individualized management for patients with LUAD and LUSC who carry a TP53-MUT, and warrant further research.

Impact Of Genetic Alterations On Outcomes Of Patients With Stage I Nonsmall Cell Lung Cancer: An Analysis Of The Cancer Genome Atlas Data

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer

Mutational Status of Main Driver Genes Influences the Prognosis of Stage I–III Lung Adenocarcinoma Patients Underwent Radical Surgery

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer

TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes

Clinical Genetic Features and Related Survival Implications in Patients with Surgically Resected Large-Cell Lung Cancer

Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma

Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy

[Gene mutation characteristics of clinical stage ⅠA lung adenocarcinoma and their relations with patients' long-term prognosis]

Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance

Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features

The Co-Mutation of EGFR and Tumor-Related Genes Leads to a Worse Prognosis and a Higher Level of Tumor Mutational Burden in Chinese Non-Small Cell Lung Cancer Patients

P2.01-45 Clinico-Molecular Characteristics and Prognostic Outcomes of TP53 Mutated Patients with Advanced Non-Small Cell Lung Cancer

Genome-Wide Analysis of Lung Adenocarcinoma Identifies Novel Prognostic Factors and a Prognostic Score.

Genomic Underpinnings of Tumor Behavior in in Situ and Early Lung Adenocarcinoma.

Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis

Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations